

DAFTAR PUSTAKA

- Akre, M., Finkelstein , M., Erikson, M., Liu, M., Vanderbilt, L., and Billman, G. (2010). Sensitivity of the Pediatric Early Warning Score to Identify Patient Deterioration. *American Academy of Pediatrics*, 763-768.
- American, Society. Thoracic., and Infectious, Society. Diseases of America. (2005). Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. *Am J Respir Crit Care Med*, 388-416.
- Banu, N., and Sukhani, V. K. (2018). Comparison of different antibiotic treatment in children with community acquired pneumonia: a comparative study. *International Journal of Contemporary Pediatrics*, 2083-2086.
- Barson, W. J., Kaplan, S. L., and Torchia, M. M. (2018). Pneumonia in Children: Epidemiology, Pathogenesis, and Etiology. *UpToDate*, 1-16.
- Berg, A. E., Inchley, C. S., Fjaerli, H. O., Leegaard, T. M., Lindbaek, M., and Nakstad, B. (2017). Clinical features and inflammatory markers in pediatric pneumonia: a prospective study. *Eur J Pediatr*, 629–638.
- Blackford , M. G., Glover, M. L., and Reed, M. D. (2015). Respiratory Tract Infections Lower, *in* : DiPiro, Joseph T., Wells B.G., Schwinghammer, Terry L., DiPiro, Cecily V. (Eds.).*Pharmacotherapy Handbook* (9 ed.). New York: McGraw-Hill, 410-417.
- Bradley, J. S., Byington, C. L., Shah, S. S., Alverson, B., Carter, E. D., Harisson, C., and Swanson, J. T. (2011). The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. *IDSA GUIDELINES*, 1-52.
- Brook, I. (2003). Unexplained fever in young children: how to manage severe bacterial infection. *British Medical Journal*, 1094-1097.
- Budijanto, D., Budiono , C. S., Kurniasih, N., Wardah, Manullang, E. V., Ismandari, F., and Sakti, E. S. (2017). *Data dan Informasi Profil Kesehatan Indonesia*. Jakarta: Kementerian Kesehatan Republik Indonesia, 142.
- California, S. H., Sinuraya, R. K., Halimah, E., and Subarnas, A. (2018). Effectiveness of Ampicillin and Ampicillin-Gentamicin for Children under Five Years Old with Pneumonia. *Jurnal Farmasi Klinik Indonesia*, 52-58.
- Chandrashekara , S., (2014). C - reactive protein: An inflammatory marker with specific role in physiology, pathology, and diagnosis. *Internet Journal of Rheumatology and Clinical Immunology*, 1-23.

- Cetinkaya, F., Gogremis, A., and Kutluk, G. (2004). Comparison of Two Antibiotic Regimens in the Empirical Treatment of Severe Childhood Pneumonia. *Indian Journal of Pediatrics*, 969-970.
- Chandra, P., Suman, P., Airon, H., Mukherjee, M., and Kumar, P. (2014). Prospects and advancements in C-reactive protein detection. *World Journal of Methodology*, 1-5.
- Coelho, L., Pova, P., Almeida, E., Fernandes, A., Mealha, R., Moreira, P., and Sabrino, H. (2007). Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. *Critical Care*, 1-9.
- Dahlan, Z. (2014). *Pneumonia; Buku Ajar Ilmu Penyakit Dalam Jilid II* (VI ed.). Jakarta: Balai Penerbit FKUI, 1608-1624.
- Dewi, R. (2016). Pediatric Early Warning Score: Bagaimana Langkah Kita Selanjutnya? *Sari Pediatri*, 68-73.
- Francisco, M. J., and Huaman, J. E. (2018). The efficacy of ampicillin vs. cephalosporins in the treatment of community acquire pneumonia in inpatient children hospital III Grau. *Int J Fam Commun Med*, 378-382.
- George, H., and MCCracken, J. R. (2000). Etiology and treatment of pneumonia. *Pediatr Infect Dis J*, XIX, 373.
- Gonzalez, A. R., Utrillo, L., Bielsa, S., Falguera, M., and Porcel, J. M. (2018). The Diagnostic Value of Serum C-Reactive Protein for Identifying Pneumonia in Hospitalized Patients with Acute Respiratory Symptoms. *Journal of Biomarkers*, 1-5.
- Gould, J. M., and Weiser, J. N. (2001). Expression of C-Reactive Protein in the Human Respiratory Tract. *Journal of Clinical and Immunology*, 1747-1754.
- Handayani, R. S., Siahaan, S. and Herman, M. J., 2017. Antimicrobial Resistance and Its Control Policy Implementation in Hospital in Indonesia. *Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan*, 131-140.
- Hariadi, S., Amin, M., Pradjoko, I., Winariani, Margono, B. P., Wibisono, M. J., and Soedarsono, P. (2010). *Ilmu Penyakit Paru* (2nd ed.). Surabaya: Departemen Ilmu Penyakit Paru FK Unair-RSUD Dr. Soetomo, 26-34.
- Huether, S. E., McCance, K. L., Brashers, V. L., and Rote, N. S. (2016). Alterations of Pulmonary Function in Children. In *Understanding Pathophysiology 6th Edition*. St. Louis, Missouri: Elsevier, 2075.
- IVAC, J. H. (2018). *Pneumonia & Diarrhea Progress Report 2018*. IVAC at Johns Hopkins Bloomberg School of Public Health, 1-40.
- Kelly, K. J., Remington, R. E., Fan, V. S. and Sloan, K. L., 2012. Predicting Antibiotic Resistance to Community-Acquired Pneumonia Antibiotics in Culture-Positive Patients With Healthcare-Associated Pneumonia. *J Hosp Med*, 1-18.

- KEMENKES. (2016). *Mari Bersama Atasi Resistensi Antimikroba (AMR)*. From <http://www.depkes.go.id/article/print/16060800002/mari-bersama-atasi-resistensi-antimikroba-amr-.html>. Retrieved April 5, 2019.
- Lassi ZS, D. J. (2014). Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age. *BMJ Publishing Group*, 1-7.
- Lee, M., Stevens, H., Chattel, M. V., Matters, J., Collins, M. S., Kendrick, T., and Patterson, S. (2018). *Infants and Children: Acute Management of Community Acquired Pneumonia. NSW Government Health Guideline*, 1-32.
- Leyenaar, J. K., Shieh, M. S., Lagu, T., Pekow, P. S., and Lindenauer, P. K. (2014). Comparative Effectiveness of Ceftriaxone in Combination with a Macrolide Compared with Ceftriaxone Alone for Pediatric Patients Hospitalized with Community Acquired Pneumonia. *Pediatric Infectious Disease Journal*, 387-392.
- Lodha, R., Kabra, S. K., and Pandey, R. M. (2013). Antibiotics for community-acquired pneumonia in children (Review). *The Cochrane Collaboration*, 1-68.
- Man, S. C., Sas, V., Schnell, C., Florea, C., Juju, A., Szilagyl, A., and Aldea, C. (2018). Antibiotic Treatment In Childhood Community Acquired Pneumonia- Clinical Practice Versus Guidelines: Results From Two University Hospital. *Clujul Medical*, 53-57.
- Mandell LA, W. R. (2007). Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. *IDSA/ATS Guidelines for CAP in Adults*, 27-72.
- Marcus, N., Mor, M., Amir, L., Mimouni, M., and Waisman, Y. (2008). Validity of the quick-read C-reactive protein test in the prediction of bacterial pneumonia in the pediatric emergency department. *European Journal of Emergency Medicine*, XV, 158-161.
- Mathura , S., Fuchs, A., Bielickia, J., Van Den Ankerb, J. N., and Sharlanda, M. (2016). Antibiotic Use for Community Acquired Pneumonia (CAP) in Neonates and Children: 2016 Evidence Update. *Paediatric Infectious Disease Research Group*, 1-21.
- McPhee, S., and Hammer , G. (2009). *Pathophysiology of Disease: An Introduction to Clinical Medicine* (7th ed.). Philadelphia, 80-85.
- Moldoveanu, B., Otmishi, P., Jani, P., Walker, J., Sarmiento, X., Guardiola, J., and Yu, J. (2009). Inflammatory mechanisms in the lung. *Journal of Inflammation Research*, 1-11.
- Ministry of Health, R. (2017). *Indonesia Health Profile*. Jakarta: Ministry of Health RI.
- Muenchhoff, M., and Goulder, P. J. (2014). Sex Differences in Pediatric Infectious Diseases. *Journal of Infectious Disease*, 120-126.
- Mushtaq, N., Shaikh, A. S., Khatwani, N. R., Mohsin, S., and Alam, M. M. (2013). Ceftriaxone versus Ampicillin in the Treatment of Pneumonia in Children. *Infectious Diseases Journal of Pakistan*, 556-559.

- Nguyen , T., Tran, T., Roberts, C., Fox, G., Graham, S., and Marais, B. (2017). Risk Factors for Child Pneumonia- focus on the Western Pacific Region. *Pediatric Respirology Rev*, 95-101.
- Ostapchuk , M., Roberts, D. M., and Haddy, R. (2004). Community-Acquired Pneumonia in Infants and Children. *American Family Physician*, 899-908.
- Pacifici, G. M. (2017). Clinical Pharmacology of Ampicillin in Neonates and Infants: Effects and Pharmacokinetics. *Int J Pediatr*, V, 6383-6410.
- Pacifici, G. M., and Marchini, G. (2017). Clinical Pharmacokinetics of Gentamicin in Neonates. *Int J Pediatr*, V, 4575-4599.
- Pacifici, M. G. (2011). Pharmacokinetics of cephalosporins in the neonate: a review. *Clinics*, 1267-1274.
- Pacifici, M. G., and Marchini, G. (2017). Clinical Pharmacology of Ceftriaxone in Neonates and Infants: Effects and Pharmacokinetics. *Int J Pediatr*, 5, 5751-5777.
- PDPI. (2003). *Pneumonia Komuniti; Pedoman Diagnosis dan Penatalaksana Di Indonesia*. Jakarta: FKUI.
- PDPI. (2014). *Pneumonia Komunitas Pedoman Praktis Diagnosis dan Penatalaksanaan di Indonesia*. Jakarta: FKUI.
- Rahajoe, N. N., Suprianyanto, B., and Setyanto, D. B. (2008). *Buku Ajar Respirologi Anak* (1st ed.). Jakarta: Badan Penerbit IDAI, 350-364.
- Salazar, J., Martinez, M. S., Castilo, M. C., Nunez, V., Anez, R., Torres, Y., and Bermudez, V. (2014). C-Reactive Protein: An In-Depth Look into Structure, Function, and Regulation. *International Scholarly Research Notices*, 1-11.
- Scaparrotta, A., Attanasi, M., Di Pillo, A., and Chiarelli, F. (2013). Pediatric Lower Respiratory Infections. *OMICS Group eBooks*, 13-23.
- Schejter, Y. D., Cymberknoh, M. C., Tenenbaum, A., Rebecca, B., Averbuch, D., Kharasch, S., and Kerem, E. (2012). Antibiotic Treatment of Children With Community-Acquired Pneumonia: Comparison of Penicillin or Ampicillin Versus Cefuroxime. *Pediatric Pulmonology*, 52-58.
- Slaats, J., Oever, J., Van de Veerdonk, F. L., and Netea, M. G. (2016). IL-1 β /IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections. *PLoS Pathog*, 1-13.
- Sproston, N. R., and Ashworth, J. J. (2018). Role of C-Reactive Protein at Sites of inflammation and infection. *Frontiers in Immunology*, 1-11.
- Titova, E., Chistensen , A., Henriksen, A. H., Steinshamn, S., and Asberg, A. (2018). Comparison of procalcitonin, C-reactive protein, white blood cell count and clinical

- status in diagnosing pneumonia in patients hospitalized with acute exacerbations of COPD: A prospective observational study. *Chronic Respiratory Disease*, 1-19.
- Torres, A., and Cilloniz, C. (2015). Epidemiology, Etiology, and Risk Factor Of Bacterial Pneumonia. In *Clinical Management Of Bacterial Pneumonia*. Switzerland: Springer, 11-12.
- Uranga, A., Espana, P. P., Bilbao, A., Quintama, J. M., Arriaga, I., and Intxausti, M. (2016). Duration of Antibiotic Treatment in Community-Acquired Pneumonia A Multicenter Randomized Clinical Trial. *JAMA Internal Medicine*, 1257-1265.
- Vazquez, E. G., Martinez, J. A., Mensa, J., Sanchez, E. G., Marcos, M. A., de Roux, A., and Torres, A. (2003). C-reactive protein levels in community-acquired pneumonia. *European Respiratory Journal*, 702-705.
- Watkins, R. R., and Lemonovich, T. L. (2011). Diagnosis and Management of Community Acquired Pneumonia in Adults. *American Academy of Family Physician*, 1299-1306.
- WHO. (2014). Revised WHO classification and treatment of childhood pneumonia at health facilities EVIDENCE SUMMARIES. *WHO Library Cataloguing-in-Publication Data*, 1-34.
- WHO. (2014). *Antimicrobial Resistance Global Report On Surveillance*. France: WHO Library Cataloguing-in-Publication Data, 1-35.
- Williams, D. J., Hall, M., Shah, S. S., Parikh, K., Tyler, A., Neuman, M. I., and Hersh, A. L. (2013). Narrow Vs Broad-spectrum Antimicrobial Therapy for Children Hospitalized With Pneumonia. *Jornal of the American Academy of Pediatrics*, 1141-1148.
- Yadav, K. K., Awasthi, S., Takia, L., Agarawal, J., and Agarwal, G. G. (2015). Procalcitonin and C-reactive protein in WHO defined severe and very severe community acquired pneumonia: A hospital based cross-sectional study. *Clin Epid Glob Heal*, 4-9.
- Zhydkov, A., Crain, M. C., Thomann, R., Hoess, C., Henzen, R., Zimmerli, Szhuetz, P. (2015). Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community acquired pneumonia. *Clin Chem Lab Med*, 559-566.